ACADIA Pharmaceuticals Inc ACAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
-
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
-
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
-
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
-
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
-
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Trading Information
- Previous Close Price
- $20.94
- Day Range
- $20.92–21.73
- 52-Week Range
- $19.69–28.35
- Bid/Ask
- $21.15 / $21.85
- Shares Outstanding
- 171.24M
- Market Cap
- $3.70B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 35.28
- Price/Sales
- 3.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 798
- Website
- https://www.acadia.com
Valuation
|
Metric
|
ACAD
|
|---|---|
Price/Earnings (Normalized) | 35.28 |
Price/Book Value | 2.89 |
Price/Sales | 3.30 |
Price/Cash Flow | 19.08 |
Price/Earnings
ACAD
Financial Strength
|
Metric
|
ACAD
|
|---|---|
Quick Ratio | 3.27 |
Current Ratio | 3.59 |
Interest Coverage | — |
Quick Ratio
ACAD
Profitability
|
Metric
|
ACAD
|
|---|---|
Return on Assets (Normalized) | 30.58% |
Return on Equity (Normalized) | 42.11% |
Return on Invested Capital (Normalized) | 37.55% |
Return on Assets
ACAD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Xptr | — | |||
| Athersys Inc
ATHXQ
| — | Nfl | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hgsnhltf | Vjmkgq | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qkfbsnfn | Njqkqz | $64B | |||
| UCB SA
UCBJF
| — | Bxhq | $61B | |||
| UCB SA ADR
UCBJY
| — | Kpzmg | $61B | |||
| argenx SE
ARGNF
| — | Pspm | $56B | |||
| argenx SE ADR
ARGX
| Gckkxbpx | Tnwl | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qpmvwzl | Xmgzb | $38B | |||
| CSL Ltd
CMXHF
| — | Cvvbcp | $36B |
United States